AHERF EV Biofoundry — Diagnostics to CommercializationCliniConnectServicesStart an Enquiry
Clinical AI and multi-omics interpretation visual with biomarker networks and analytics panels

AHERF EV Biofoundry Overview

The Biofoundry connects clinical entry, scientific execution, quality and translational outputs in one integrated platform.

4 platform areas
EntryClinical Access

Clinical questions, departments and disease consortiums enter through CliniConnect.

CliniConnect
ExecutionBiomarker Works

EV, liquid biopsy, biomarker and assay workflows are shaped into reproducible project routes.

Includes EV-Works
ConfidenceQuality Gate

Quality, documentation, reproducibility and benchmarking are built into the workflow.

Includes EV-Qual™
TranslationClinical Translation

Outputs move toward clinical interpretation, AI modelling, publications, grants, IP or partner handoff.

Output pathway

Platform operating flow

Clinical Question→CliniConnect→EV-Works Biofoundry→EV-Qual™→Clinical AI Platform→Output
capabilities
Clinical question intakeDisease consortium linkageDepartment engagementFeasibility discussionClinical metadata linkageCohort feasibilityClinician feedback loopPlatform handoff to EV-Works
CliniConnect links clinicians, departments and disease consortiums to AHERF-CMBRC’s translational execution platforms. It ensures that platform work begins from real clinical questions and clinically meaningful use cases.
Links to
EV-Works BiofoundryEV-Qual™Clinical AI PlatformServicesIncubationGrants and academic collaboration
EV-Works capabilities
EV-Works is the central execution platform for EV workflows, biomarker development, diagnostics, liquid biopsy, cell-free therapeutics, vaccines, immunomodulation and drug delivery systems. It converts clinical and scientific concepts into reproducible workflows, datasets, assays, panels and translational development packages.
Subitems
EV workflow designEV isolation and enrichmentEV characterizationParticle analysisEV marker assessmentCargo profilingWorkflow optimizationDocumentation and reproducibility
Source systems / sample types
Plasma / serum EVsUrinary EVsSalivary EVsTear-derived EVsCell culture-derived EVsStem-cell-derived EVsImmune-cell-derived EVsTumor-derived EV modelsDisease-specific biofluid EVs where applicable
This is the technical engine for reproducible EV isolation, characterization, cargo analysis and workflow development across diagnostic, biomarker and therapeutic use cases.
Subitems
EV cargo biomarkersProtein biomarkersTranscript biomarkerscfDNA / ctDNA-linked markersInflammatory and immune signaturesMulti-marker panelsDisease-linked biomarker discoveryBiomarker prioritization
This area supports the development of disease-linked biomarkers using EV cargo, proteins, transcripts, nucleic acids, immune signals and multi-marker panels.
Subitems
EV-based diagnosticsMolecular diagnostic panelsReportable biomarker modelsRisk-score conceptsEarly detection panelsPrognostic assaysMonitoring assaysDiagnostic interpretation frameworksLDT-readiness support where applicable
This area converts biomarker concepts into diagnostic development pathways, including panel design, risk-score logic, report models, diagnostic interpretation and translation-readiness planning.
Subitems
EV-based liquid biopsyBlood-based workflowsUrine-based workflowsSaliva-based workflowsTear-based workflowscfDNA / ctDNA integrationProtein and transcript panelsCross-disease liquid biopsy models
This area supports non-invasive and minimally invasive biomarker workflows across oncology, neurology, renal disease, ophthalmology, reproductive health and precision medicine.
Subitems
EV therapeuticsExosome-based therapeutic conceptsStem-cell-derived EVsImmune-cell-derived EVsRegenerative medicine conceptsAnti-inflammatory EV effectsTissue repair conceptsPotency-linked assay designSafety and comparability thinking
This area supports EV and cell-free therapeutic development concepts, including potency-linked assays, biological activity readouts and translational therapeutic workflows.
Subitems
EV-based vaccine conceptsAntigen-presentation biologyImmune activation profilingImmune-response biomarkersCancer vaccine conceptsInfection vaccine conceptsImmunomodulatory EV effectsImmune monitoring panels
This area supports vaccine-linked, immune-monitoring and EV-immunomodulation workflows, including immune activation, antigen presentation, vaccine-response biomarkers and cancer or infection vaccine concepts.
Subitems
EV-mediated drug deliveryExosome-loaded therapeuticsRNA / miRNA / siRNA deliveryProtein and peptide deliverySmall-molecule loadingTargeted delivery conceptsBlood–brain barrier delivery conceptsFormulation workflowsStability workflows
This area supports EV-based and exosome-based delivery systems for payload loading, targeting, formulation, stability and disease-specific therapeutic delivery concepts.
capabilities
Quality gatesPre-analytical controlsEV characterization thresholdsBatch reproducibilityInter-run controlsAcceptance criteriaMISEV-aligned documentationAudit-ready QC recordsBenchmarking workflowsMethod comparabilityPotency-linked assay documentationTherapeutic comparabilityStability and storage documentationRelease-criteria thinking for advanced EV workflows
EV-Qual supports reproducibility, benchmarking and quality documentation across EV-Works workflows, including biomarker, diagnostic, liquid biopsy, therapeutic, vaccine and drug delivery applications.
capabilities
Data curationFeature engineeringBiomarker integrationComposite biomarker scoringPredictive modellingPrognostic modellingROC / calibration analysisClinical utility analysisMultimodal risk modelsReport visualizationModel documentation
The Clinical AI Platform converts biomarker, EV, liquid biopsy, clinical and multimodal data into risk scores, predictive models, clinical interpretation frameworks, longitudinal monitoring tools and reportable decision-support outputs.

Platform outputs

The platform stack can generate outputs depending on project scope and maturity.

Biomarker panelsEV datasetsDiagnostic conceptsLiquid biopsy workflowsCell-free therapeutic conceptsDrug delivery prototypesVaccine and immunomodulation conceptsAI risk modelsQC reportsPublicationsPatentsGrant-ready packagesPartner collaboration packages

Translation-readiness bridge

DocumentationQuality gatesMethod reproducibilityAssay acceptance criteriaReport structureIP / patent support linkageGovernance linkagePartner / incubation handoff
Project scoping: Platform access is shaped around scientific goals, feasibility, available workflows and collaboration needs.
Therapeutic development: Therapeutic, vaccine and drug delivery programs are positioned as research and translational development platforms, with safety, potency, comparability and regulatory-readiness considerations built progressively into the workflow.